Varicella-zoster virus (VZV) causes chickenpox and shingles, while herpes simplex virus (HSV) is responsible for oral and genital herpes. Although current treatments mainly focus on inhibiting viral replication, there is a critical need for new therapies to address the limitations and side effects associated with existing treatments.

Harvard University has filed a lawsuit claiming the Trump administration’s freezing of its federal funding is unlawful and beyond the government’s authority. Announcing the move, Harvard’s president, Alan Garber, highlighted the impact of freezing $2.2 billion in grants – and the threat to freeze a further $1.1 billion – will have on the university’s biomedical research.

The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and medical research charity Lifearc have announced a collaboration to develop an affordable and accessible monoclonal antibody (mAb) therapeutic for Crimean-Congo hemorrhagic fever virus (CCHFV).

After more than three years of discussion, the World Health Organization’s Intergovernmental Negotiating Body (INB) has agreed on a proposal to prevent, prepare and respond to a pandemic. The plan is born, the INB proposal said, out of inequities around the world that slowed timely and equitable access to health products to respond to the COVID-19 pandemic.

At the recent European Society of Clinical Microbiology and Infectious Diseases (ESCMID) meeting in Vienna, Longhorn Vaccines & Diagnostics LLC presented data on the neutralizing antibody responses of LHNVD-202, an unconjugated composite peptide vaccine.